- Email: [email protected]
Activated, antigen-expressing dendritic cells; transgenic dendrite cell culture for use in stimulating immune response
PII: SO264-410X(98)00189-3
Vaccine, Vol. 16, No. 13, p. 1349, 1998 Published by Elsevier Science Ltd Printed in Great Britain 0264-410X/98 $19+0.00
ELSEVIER
Patent Report This section provides information on worldwide patents relevant to vaccine design and production. The Patent Report gives the following information: title of patent, patentee, patent number, publication date and summary of the patent. A number of patents in this report are reproduced from ‘Biotechnology Abstracts’ with permission of Derwent Publications Ltd, Rochdale House, 128 Theobalds Road, London WClX 8RD. Chemohine receptor CCR5 fragments; chemokine receptor and HIV virus-l envelope protein production for use in AIDS therapy and as a recombinant vaccine Progenies Pharmaceuticals: Aaron Diamond Aids Res. Cent. New York World 9747 318; 18 December 1997 A protein (I) having a protein sequence corresponding to the sequence of a chemokinc receptor, especially CCRS, is claimed, where (I) is capable of inhibiting HIV virus-l infection of the cells. Also claimed are: a protein corresponding to part of a HIV virus-l envelope glycoprotein capable of specifically binding to the chemokine receptor CCRS; an antibody or antibody fragment capable of binding to a chemokine receptor on a CD4+ cell and inhibiting HIV virus-l infection of the cell; a non-chemokine agent capable of binding to CCR5 and inhibiting the fusion of HIV virus-l to CD4+ cells; a non-human transgenic animal which contains an isolated DNA molecule encoding CCR5 and optionally DNA encoding fusion; and a transformed cell which contains an isolated nucleic acid molecule encoding CCRS. Both (I) and the HIV virus-l env protein are used for HIV virus-l therapy or as recombinant vaccines for disease prevention. The non-chemokine agent and antibody are used for HIV virus-l therapy. 021-98 Activated, antigen-expressing dendritic ceils; transgenic dendrite cell culture for use in stimulating immune response Immunex World 9801538; 15 January 1998 A new population of activated dendrite cells expressing an antigen are produced by exposing dendritic cells to the antigen in culture under conditions promoting uptake and processing of the antigen, or transfecting the cells with a gene encoding the antigen, and activating the antigen-expressing dendritic cells by exposing them to a CD40 binding protein (CBP) capable of inhibiting binding of CD40 to CD40L. The dendritic cells are produced by contacting hematopoietic stem or progenitor cells with granulocyte hematopoietic stem or progenitor cells with granulocyte-macrophage colony stimulating factor (GM-CSF), flt-3L, interleukin (IL)-4, tumor necrosis factor-alpha, IL-3, c-kit ligand and/or fusions of GM-CSF and IL-3. The CBP preferably has a specified protein sequence and is encoded by DNA. The dendritic cells may be administered to an individual for stimulating an immune response, or may be allowed to present the antigen to T-lymphocytes ex vivo, to prepare antigen-specific T-cells. The T-cells can then be readministered to the individual. 022-98 Attenuated respiratory-syncytiai virus vaccine; mutant virus vaccine US. Dep. Health Hum. Sen! World 9802 530; 22 January 1998 As new isolated infectious recombinant respiratory-syncytial virus (RSV) for use as a vaccine contains an RSV genome or antigenome, a major nucleocapsid protein, a nucleocapsid
1349
Vaccine 1998 Volume 16 Number 13
phosphoprotein, a large polymerase and an RNA-polymerase (EC 2.7.7.6) elongation factor. The RSV has at least two attenuating mutations, one specifying a ts mutation substitution in the polymerase gene or the initiation codon of the M2 gene. The RSV may also contain a modification inducing altered growth characterics or immunogenicity, attenuation, cold adaptation, small plaque size or host range restriction. The RSV genome or antigenome may be modified to encode a non-RSV molecule, e.g. cytokine, T-cell helper factor, restriction site market, or a protein from a microbial pathogen capable of eliciting an immune response. Other modifications are also claimed. Also claimed are RSV strains 248 (ATCC VR2450), cpts-2481404 (ATCC VR2454), cpts248/955 (ATCC VR2453), cpts-530 (ATCC VR2452), cpts530/1009 (ATCC VR2451), cpts-530.1030 (ATCC VR2455), B-l cp5212B5 (ASTCC VR2542) and B-l cp23 (ATCC VR). 023-98 Mixture of fusion, attachment and matrix proteins from respiratory-syncytiai virus; and monoclonal antibody production for use in diagnosis and vaccine Connaught Lab World 9802 457; 22 January 1998 A mixture of purified multimeric fusion (F) protein (including heterodimers of mol.wt 70000, dimeric and trimeric forms when analyzed under non-reducing conditions), attachment (G) protein (including G protein of mol.wt 95000, G protein of mol. wt 55000 and an oligomeric G protein under non-reducing conditions) and matrix (M) protein (mol. wt 28000-34000, preferably 31000 by SDS-PAGE) of respiratory-syncytial virus (RSV). When analyzed by SDS-PAGE, the F protein consists of Fl (molwt 48000) and F2 (molwt 23000) and the G protein consists of a G protein of mol.wt 95000 and a G protein of mol.wt 55000. The mixture can be used in vaccines to protect primates, preferably humans, against RSV. The mixture preferably contains, by wt, 35-70% F, 5-30% G and lo-40% M, with an Fl :F2 ratio of l-2: 1. Also claimed is a method of producing mouse monoclonal antibodies specific for the F, G and M proteins by hybridoma cell culture. 024-98 Live gut-colonizing microorganism for use in vaccines; colonization gene mutation, for use in e.g. fowl immunization against Salmonella sp. MFF UK. World 9802 523; 22 January 1998 A live gut-colonizing microorganism (I) may be used in a new vaccine, inducing an immune response and has a mutation that reduces the ability of (I) to colonize the alimentary tract, (I) may naturally cause food poisoning, and may be used to immunize humans, farm animals or pets, especially to immunize fowl against Salmonella sp. (I) may optionally be engineered to express heterologous antigens. (I) may be Enterobacteriaceae, e.g. Escherichia coli, Yersinia sp., Campylobacter sp., Campylobacter sp., Listeria sp., Bacillus cerreus, Shigella sp ., or Salmonella sp. (preferred). The mutation down-regulates or inactivates at least one gene associated with colonization, specifically hupA, dksA, rfaY, sipC or clpB. (I) may also express a heterologous antigen or include a negative serotype market, and may have a further mutation of the aro-A, gal-E, pur-A genes or an electron transport gene. Random mutagenesis is performed on (I), e.g. using transposons, then selection is made for reduction of colonizing properties. 025-98
Vaccine, Vol. 16, No. 13, p. 1349, 1998 Published by Elsevier Science Ltd Printed in Great Britain 0264-410X/98 $19+0.00
ELSEVIER
Patent Report This section provides information on worldwide patents relevant to vaccine design and production. The Patent Report gives the following information: title of patent, patentee, patent number, publication date and summary of the patent. A number of patents in this report are reproduced from ‘Biotechnology Abstracts’ with permission of Derwent Publications Ltd, Rochdale House, 128 Theobalds Road, London WClX 8RD. Chemohine receptor CCR5 fragments; chemokine receptor and HIV virus-l envelope protein production for use in AIDS therapy and as a recombinant vaccine Progenies Pharmaceuticals: Aaron Diamond Aids Res. Cent. New York World 9747 318; 18 December 1997 A protein (I) having a protein sequence corresponding to the sequence of a chemokinc receptor, especially CCRS, is claimed, where (I) is capable of inhibiting HIV virus-l infection of the cells. Also claimed are: a protein corresponding to part of a HIV virus-l envelope glycoprotein capable of specifically binding to the chemokine receptor CCRS; an antibody or antibody fragment capable of binding to a chemokine receptor on a CD4+ cell and inhibiting HIV virus-l infection of the cell; a non-chemokine agent capable of binding to CCR5 and inhibiting the fusion of HIV virus-l to CD4+ cells; a non-human transgenic animal which contains an isolated DNA molecule encoding CCR5 and optionally DNA encoding fusion; and a transformed cell which contains an isolated nucleic acid molecule encoding CCRS. Both (I) and the HIV virus-l env protein are used for HIV virus-l therapy or as recombinant vaccines for disease prevention. The non-chemokine agent and antibody are used for HIV virus-l therapy. 021-98 Activated, antigen-expressing dendritic ceils; transgenic dendrite cell culture for use in stimulating immune response Immunex World 9801538; 15 January 1998 A new population of activated dendrite cells expressing an antigen are produced by exposing dendritic cells to the antigen in culture under conditions promoting uptake and processing of the antigen, or transfecting the cells with a gene encoding the antigen, and activating the antigen-expressing dendritic cells by exposing them to a CD40 binding protein (CBP) capable of inhibiting binding of CD40 to CD40L. The dendritic cells are produced by contacting hematopoietic stem or progenitor cells with granulocyte hematopoietic stem or progenitor cells with granulocyte-macrophage colony stimulating factor (GM-CSF), flt-3L, interleukin (IL)-4, tumor necrosis factor-alpha, IL-3, c-kit ligand and/or fusions of GM-CSF and IL-3. The CBP preferably has a specified protein sequence and is encoded by DNA. The dendritic cells may be administered to an individual for stimulating an immune response, or may be allowed to present the antigen to T-lymphocytes ex vivo, to prepare antigen-specific T-cells. The T-cells can then be readministered to the individual. 022-98 Attenuated respiratory-syncytiai virus vaccine; mutant virus vaccine US. Dep. Health Hum. Sen! World 9802 530; 22 January 1998 As new isolated infectious recombinant respiratory-syncytial virus (RSV) for use as a vaccine contains an RSV genome or antigenome, a major nucleocapsid protein, a nucleocapsid
1349
Vaccine 1998 Volume 16 Number 13
phosphoprotein, a large polymerase and an RNA-polymerase (EC 2.7.7.6) elongation factor. The RSV has at least two attenuating mutations, one specifying a ts mutation substitution in the polymerase gene or the initiation codon of the M2 gene. The RSV may also contain a modification inducing altered growth characterics or immunogenicity, attenuation, cold adaptation, small plaque size or host range restriction. The RSV genome or antigenome may be modified to encode a non-RSV molecule, e.g. cytokine, T-cell helper factor, restriction site market, or a protein from a microbial pathogen capable of eliciting an immune response. Other modifications are also claimed. Also claimed are RSV strains 248 (ATCC VR2450), cpts-2481404 (ATCC VR2454), cpts248/955 (ATCC VR2453), cpts-530 (ATCC VR2452), cpts530/1009 (ATCC VR2451), cpts-530.1030 (ATCC VR2455), B-l cp5212B5 (ASTCC VR2542) and B-l cp23 (ATCC VR). 023-98 Mixture of fusion, attachment and matrix proteins from respiratory-syncytiai virus; and monoclonal antibody production for use in diagnosis and vaccine Connaught Lab World 9802 457; 22 January 1998 A mixture of purified multimeric fusion (F) protein (including heterodimers of mol.wt 70000, dimeric and trimeric forms when analyzed under non-reducing conditions), attachment (G) protein (including G protein of mol.wt 95000, G protein of mol. wt 55000 and an oligomeric G protein under non-reducing conditions) and matrix (M) protein (mol. wt 28000-34000, preferably 31000 by SDS-PAGE) of respiratory-syncytial virus (RSV). When analyzed by SDS-PAGE, the F protein consists of Fl (molwt 48000) and F2 (molwt 23000) and the G protein consists of a G protein of mol.wt 95000 and a G protein of mol.wt 55000. The mixture can be used in vaccines to protect primates, preferably humans, against RSV. The mixture preferably contains, by wt, 35-70% F, 5-30% G and lo-40% M, with an Fl :F2 ratio of l-2: 1. Also claimed is a method of producing mouse monoclonal antibodies specific for the F, G and M proteins by hybridoma cell culture. 024-98 Live gut-colonizing microorganism for use in vaccines; colonization gene mutation, for use in e.g. fowl immunization against Salmonella sp. MFF UK. World 9802 523; 22 January 1998 A live gut-colonizing microorganism (I) may be used in a new vaccine, inducing an immune response and has a mutation that reduces the ability of (I) to colonize the alimentary tract, (I) may naturally cause food poisoning, and may be used to immunize humans, farm animals or pets, especially to immunize fowl against Salmonella sp. (I) may optionally be engineered to express heterologous antigens. (I) may be Enterobacteriaceae, e.g. Escherichia coli, Yersinia sp., Campylobacter sp., Campylobacter sp., Listeria sp., Bacillus cerreus, Shigella sp ., or Salmonella sp. (preferred). The mutation down-regulates or inactivates at least one gene associated with colonization, specifically hupA, dksA, rfaY, sipC or clpB. (I) may also express a heterologous antigen or include a negative serotype market, and may have a further mutation of the aro-A, gal-E, pur-A genes or an electron transport gene. Random mutagenesis is performed on (I), e.g. using transposons, then selection is made for reduction of colonizing properties. 025-98